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ABSTRACT 
Aims: This systematic review and meta-analysis consolidates recent evidence on the 
effectiveness of lifestyle-based, weight loss interventions for adults with type 2 diabetes.  
Materials and methods: A literature search from January 2003 to July 2013 was conducted 
(PubMed, Embase, CINAHL and Web of Science). Eligible studies were randomized 
controlled trials evaluating weight loss interventions (diet and physical activity, with or 
without behavioral strategies) of ≥12-weeks duration, compared to usual care or other 
comparison intervention. Ten studies were included for review. Some heterogeneity was 
present in the sample, thus random-effects models were used to calculate pooled effects.  
Results: Intervention duration ranged from 16-weeks to nine years, with all but one delivered 
via individual or group face-to-face sessions. From six studies comparing lifestyle 
intervention to usual care the pooled effect on weight (n=5,795) was -3.33kg (95% CI: -5.06, 
-1.60kg), and on HbA1c (n=5,784) was -0.29% (95% CI: -0.61, 0.03%), with both attenuated 
in sensitivity analyses. The pooled within-group effect on weight (n=3,063) from all ten 
lifestyle intervention groups was -5.33kg (95% CI: -7.33, -3.34kg), also attenuated in 
sensitivity analyses. No participant or intervention characteristic examined explained the 
heterogeneity. Only one study assessed whether intervention effects were maintained 
following the end-of-intervention.  
Conclusions: Lifestyle-based weight loss intervention trials in type 2 diabetes achieve, on 
average, modest reductions in weight and HbA1c, but results were heavily influenced by one 
trial. Evidence-based approaches for improving the effectiveness of lifestyle-based 
interventions in type 2 diabetes are needed along with future studies reporting on 
maintenance and cost-effectiveness.    
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INTRODUCTION  
The prevalence of type 2 diabetes continues to increase globally [1]. Recent estimates 
indicate that 11.3% of adults in the United States [2], 4.5% in the United Kingdom [3] and 
7.4% in Australia [4] are affected by type 2 diabetes.   
Obesity increases the risk of developing type 2 diabetes, and  complicates management in 
those with the disease by increasing insulin resistance and blood glucose levels, and 
increasing risk of  dyslipidemia, hypertension, cardiovascular disease and mortality [6].  
Modest weight loss of 5-10% of total body weight is recommended for overweight or obese 
people with type 2 diabetes as it can improve glycemic control, reduce the need for diabetes 
medications, and improve cardiovascular risk factors [6,7,9].   
While surgical and pharmacological interventions are effective at achieving significant 
weight loss [10], lifestyle-based interventions focusing on diet and physical activity remain 
the cornerstone of weight loss approaches [11,12]. However, current evidence suggests that 
lifestyle interventions for people with type 2 diabetes may not be effective for improving 
longer-term health outcomes such as all-cause mortality [15], thus further research is needed 
to better understand the effectiveness of such interventions.  
A systematic review and meta-analysis published in 2004 [8] reviewed the long-term 
effectiveness of lifestyle-based weight loss intervention trials in adults with type 2 diabetes, 
suggesting such interventions achieve modest weight loss and improvements in hemoglobin 
A1c (HbA1c) at 1-2 years follow-up [8].  
The aim of this systematic review and meta-analysis was to synthesize recent evidence from 
the previous 10 years on the effectiveness of lifestyle-based weight loss interventions on 
change in weight and HbA1c in adults with type 2 diabetes.  
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MATERIALS AND METHODS 
The conduct and reporting of this review adhered to guidelines outlined in the Preferred 
Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) Statement [16]. 
Data Sources and Searches 
A structured search of the following databases was conducted from January 2003 to July 
2013: PubMed, Embase, Cumulative Index to Nursing and Allied Health Literature 
(CINAHL) and Web of Science (an example of the search strategy is shown in Appendix S1). 
Searches were limited to adults and English-language publications. A manual search of 
journals expected to have the highest relevance was also conducted from January 2003-July 
2013: Diabetes Care, the International Journal of Obesity and Related Metabolic Disorders, 
Obesity Research, Obesity, the American Journal of Clinical Nutrition, and the Journal of 
American Dietetic Association. Reference lists of included studies were examined and 
authors were contacted if data were missing.  
Study Selection  
Following the search, two authors (COT and CLB) removed duplicates and screened titles 
and abstracts for relevant articles based on eligibility criteria. Studies were included if they: 
(1) reported on intervention outcomes from a randomized trial; (2) were conducted in adults 
with clinically diagnosed type 2 diabetes mellitus; (3) primarily focused on weight loss; (4) 
included a lifestyle-based only intervention as one of the study groups targeting weight loss 
through diet and physical activity, with or without explicitly defined behavioral strategies; 
and (5) had comparison groups which could be control/usual care or other intervention 
groups (e.g. pharmacological/surgical). Studies were excluded if: (1) intervention duration 
was less than 12-weeks; (2) weight change and HbA1c outcomes were not reported; (3) they 
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were in abstract form or conference proceedings only; (4) focused on general diabetes self-
management; and (5) primarily compared different dietary compositions. All decisions were 
checked with author MMR and uncertainty was resolved with discussion. Full text articles 
were retrieved for remaining records.  
Data Extraction and Quality Assessment  
Detailed information on methodology (e.g. study design, sample size and study assessments), 
participant characteristics (e.g. mean age, mean body mass index [BMI] and gender 
distribution), intervention details (e.g. intensity, frequency and duration of contact and mode 
of delivery) and the intervention effect (i.e. mean [SD] change from baseline to follow-up for 
weight and HbA1c outcomes) were extracted and tabulated. Attempts were made to contact 
authors if data were missing. 
Methodological quality of studies was evaluated with an established quality score (0-10) 
[17,18]; using a tool adapted from the CONSORT statement for randomized controlled trials 
[19]. One point was awarded for each item scored as ‘present’ (✓) and zero points were 
awarded for each item scored as ‘absent’ (X) or ‘unclear or inadequately described’ (?). Each 
study was assigned a risk of bias category based on the following cut-offs for quality scores: 
high risk (0-3), moderate risk (4-7) and low risk (8-10). The methodological quality items 
included: (1) baseline results reported separately for each group; (2) randomization clearly 
described and adequately done (i.e. describes sequence generation and allocation 
concealment); (3) acceptable attrition (i.e. ≤20% for follow-up periods up to six months; or 
≤30% for follow-up periods over six months); (4) assessor blinding; (5) weight outcomes 
assessed at least six months after baseline; (6) intention-to-treat analysis and an appropriate 
approach to missing data; (7) potential confounders including baseline level of behavior 
appropriately accounted for in analyses; (8) summary results presented with estimated effect 
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size (between-group difference) and precision estimates; (9) power calculation reported and 
study adequately powered; and (10) weight was objectively measured. Two researchers 
independently assessed trials and discrepancies were discussed and verified.  
Data Synthesis and Analysis  
Meta-analyses were performed for changes in weight (kg) and HbA1c (%). Studies were 
included in between-group meta-analyses if they compared an intervention with usual 
care/brief diabetes education and either reported end-of-intervention effects (differences 
between groups and standard error) directly, or enough information to calculate these. 
Whenever possible, intervention effects were based on change from baseline, otherwise 
follow-up values were used. Lifestyle intervention groups from all studies were included in 
the within-group meta-analysis for change in weight (kg). Heterogeneity was tested using 
Cochran’s Q test [20]. Publication bias was tested using Egger’s test for small study effects 
[21] (Stata version 12.1; StataCorp LP, College Station, Texas). Meta-analyses were run in 
Review Manager (version 5.2). To calculate the pooled effects, random-effects (DerSimonian 
and Laird [22]) or fixed-effects models, as appropriate, were performed.  
Sensitivity analyses were performed using the leave-one-out method to assess whether results 
remained stable, regardless of which studies were included/excluded from analyses, and 
excluding studies considered to have high risk of bias. To evaluate considerable 
heterogeneity, a post-hoc, random-effects meta-regression was performed (Stata version 12.1; 
StataCorp LP, College Station, Texas) to examine associations between age, sex, BMI, 
HbA1c, intervention duration (<12months vs. ≥12months), intervention delivery (individual 
vs. group-based contact; multidisciplinary team vs. individual facilitator), physical activity 
components (≥175mins/week goal vs. less; some supervised sessions vs. none), dietary 
components (meal replacement use vs. none; energy restriction vs. general reduction), and 
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behavioral components (behavioral strategies used vs. none; self-monitoring; motivational 
interviewing), and changes in weight.  
RESULTS  
The search identified 2,506 records; 1,444 once duplicates were removed. Of these, 1,343 
records were excluded based on title/abstract, leaving 101 full-text articles for review (Figure 
1). Eleven individual studies (from 14 publications) met eligibility criteria, however one 
study was subsequently excluded as it targeted a highly specific sample of people with type 2 
diabetes (i.e. also diagnosed with schizophrenia), leaving ten individual studies (from 13 
publications) for review [10,23-31].  Appendix S2 shows detailed study, sample and 
intervention characteristics of included studies.  
The ten studies recruited samples ranging from 27 to 5,145 participants. The reported mean 
age was, on average, 55 years (range, 47 to 60 years). The average proportion of female 
participants within studies was 59% (range, 37 to 100%). Mean baseline BMI was 35.7kg/m² 
(range, 30.0 to 38.2kg/m²) and mean baseline HbA1c was 7.9% (range, 7.3 to 9.8%). 
Intervention duration ranged from 16-weeks to nine years. Nearly all (nine-of-ten) studies 
delivered their interventions via face-to-face individual [10,26,30] or group-based [24] 
sessions, or some combination [23,25,27,28,31]. One study delivered the intervention via the 
telephone [29]. Six studies compared lifestyle intervention to a control group, which received 
usual care or some form of brief diabetes education [24,25,27-29,31]. The other four studies 
compared lifestyle intervention to an intervention comparison group (i.e. no control) 
[10,23,26,30]. 
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Risk of Bias within Studies 
Appendix S3 displays the methodological quality score and risk of bias assessment. The 
median quality score was 6 (minimum-maximum: 1-9); only two studies were considered to 
have low risk of bias [29,31], six were considered to have moderate risk [10,23,24,26-28] and 
two were considered to have high risk [25,30].  
Effectiveness of Lifestyle-based Interventions for People with Type 2 Diabetes 
Appendix S4 shows results based on changes in weight and HbA1c from baseline. 
Weight change  
Compared with usual care/brief diabetes education (n=5,795), lifestyle intervention showed a 
statistically significantly greater reduction in weight, with a pooled effect of -3.33kg (95% 
CI: -5.06, -1.60kg), equivalent to approximately 3.3% of initial body weight (Figure 2A); 
however significant heterogeneity was observed (Q=53.70, p<0.001). The leave-one-out 
sensitivity analysis showed pooled effects were attenuated excluding the trial by Luley et al (-
1.99kg [95% CI: -2.77, -1.21kg] [24]), (i.e. the single trial explaining the heterogeneity and 
with the largest intervention effect). Comparatively, further analysis showed pooled effects 
were considerably larger including the Look AHEAD trial’s 1-year instead of 8-year weight 
change (-4.51kg [95% CI: -8.09, -0.93kg]) [33]. Excluding the one low quality study [25] did 
not alter the pooled effect observed.     
Lifestyle intervention groups from all 10 studies (n=3,063) were included in the meta-
analysis for within-group change in weight (Figure 2B). Lifestyle interventions, on average, 
achieved a statistically significant reduction in weight of -5.33kg (95% CI: -7.33, -3.34kg), 
equivalent to approximately 5.4% of initial body weight, however significant heterogeneity 
was observed (Q=381.04, p<0.001). The leave-one-out sensitivity analysis showed pooled 
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effects were considerably smaller excluding the trial by Snel et al (-3.41kg [95% CI: -5.04, -
1.79kg]) [30]. Excluding the two trials considered to have high risk of bias [25,30] resulted in 
similar attenuation of pooled effects. No single trial explained the heterogeneity, and meta-
regression found no significant associations between the 14 participant or intervention 
characteristics examined and weight change (Appendix S5).   
HbA1c change 
Compared with usual care/brief diabetes education (n=5,784), lifestyle intervention showed a 
non-significant pooled trend toward a reduction in HbA1c of -0.29% (95% CI: -0.61, 0.03%; 
Figure 3); however significant heterogeneity was observed (Q=38.12, p<0.001). The leave-
one-out sensitivity analysis showed pooled effects were considerably smaller excluding the 
trial by Luley et al (-0.10% [95% CI: -0.20, -0.01%], Q=1.20, p=0.877) [24]. Further analysis 
showed pooled effects were larger including the Look AHEAD trial’s 1-year instead of end-
of-intervention HbA1c change (-0.38% [95% CI: -0.67, -0.09%]) [33]. The pooled effect 
remained similar excluding the one low quality study [25]. 
 
Evidence for informing translation 
Only one study [23] assessed whether improvements in outcomes were maintained following 
a period of no intervention contact; and did not report successful maintenance of outcomes 
[23]. None of the trials included reported on cost-effectiveness of the lifestyle interventions, 
although two are proposed [32,35]. 
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DISCUSSION 
This systematic review and meta-analysis synthesizes recent evidence on the effectiveness of 
lifestyle-based weight loss interventions for adults with type 2 diabetes over the previous 
decade. Compared with usual care or brief diabetes education, such interventions achieved 
modest reductions in weight and modest improvements in HbA1c. These results are 
remarkably similar to those found in an earlier review [8], which reported similarly modest 
declines in weight (-1.7kg, or equivalent to 3.1% of initial body weight) and HbA1c level (-
0.3%), after 1-2 years of follow-up, compared with usual care or brief diabetes education.  
Modest weight loss of at least 5% of body weight is encouraged for people with type 2 
diabetes who are overweight or obese [36] and has been shown to reduce health risks 
[6,7,9,11]. Findings from pooled results of within-group change suggest that, lifestyle 
interventions may, on average, achieve this degree of weight loss. However, importantly 
there was considerable heterogeneity in the lifestyle interventions included, and the effects on 
weight loss were largely influenced by three studies [24,30,33]. None of the participant or 
intervention characteristics explored were associated with within-group weight changes, 
however this may be limited by the relatively small number of studies included [37].     
Mean weight losses of at least 5% were achieved in only three lifestyle intervention groups 
and three comparison treatment groups; although one of these trials [26] included, the now 
withdrawn,  sibutramine [38]. The remaining of these intervention protocols all differed 
considerably. The largest weight losses were observed with a short-term very low calorie diet 
(VLCD) (16 weeks), with and without the addition of exercise [30] and longer-term 
laparoscopic adjustable gastric banding (LAGB) surgery (24 months) [10]. The intervention 
by Luley et al [24], which achieved 11.3% mean weight loss after six-months required 
participants pay a fee to be involved (€150).  This financial obligation may have impacted on 
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weight loss through increased compliance [39], and possibly limited representativeness of the 
sample recruited. The Look AHEAD intervention also achieved weight loss ≥5% [31]. This 
highly resourced and intensive intervention encouraged the use of meal replacements 
(provided free of charge) [35]. Consumption of meal replacements was strongly associated 
with weight loss after one-year in the Look AHEAD intervention [40].  
Improvements in glycemic control favorably improve health outcomes for people with type 2 
diabetes by decreasing risk of diabetes complications [36,41]. While a 1% reduction in 
HbA1c has been associated with significant reductions in microvascular and macrovascular 
complications and diabetes-related mortality [41], smaller reductions in the order of 0.5% 
have also been associated with clinically meaningful improvements in cardiovascular disease 
risk factors [42]. Our meta-analysis revealed that lifestyle-based weight loss interventions 
reduced HbA1c on average by 0.29%; a magnitude similar to that observed in physical 
activity-only interventions in type 2 diabetes [43,44]. This review supports that larger 
reductions in HbA1c (in order to produce clinical benefit), are unlikely without substantial 
weight losses [12,13], or unless baseline HbA1c is >8%, as observed in other studies [45].   
Of the treatment groups that achieved clinically meaningful mean weight losses (>5%), 
reductions in mean HbA1c of ≥1% were observed in the LAGB surgery and VLCD (with and 
without the addition of exercise) treatment groups only, where weight losses were, on 
average, >20% of initial body weight [10,30]. Bariatric surgery (i.e. gastric banding/bypass 
surgery) has been shown to induce diabetes remission in morbidly obese, type 2 diabetes 
patients, which may be maintained for over two years [46] and up to eight years [47]. 
However, bariatric surgery is only considered in patients with type 2 diabetes and BMI 
>35kg/m2, where lifestyle and pharmacological therapy have been ineffective [36]. For adults 
with a BMI <35kg/m2 and type 2 diabetes, bariatric surgery has shown some short-term 
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benefits but long-term outcomes are unknown [48,49]; thus it is not currently recommended 
as part of routine medical care [36]. While VLCD treatment can achieve initial weight loss of 
a similar magnitude to bariatric surgery [50], maintenance of weight loss [50,51] is less 
successful than that observed following bariatric surgery [52].  
Only one study assessed whether intervention effects were maintained following the end-of- 
intervention [23]; while a follow-up assessment is planned for an ongoing trial [32]. Aas et al 
[23] reported weight regain and HbA1c regression to baseline levels in the lifestyle 
intervention group 12-months after intervention completion. This finding needs to be 
interpreted with caution, however, as details on this follow-up assessment were poorly 
reported. It is surprising that there has been such limited attention to assessment of longer-
term outcomes following lifestyle interventions. This is particularly important in the context 
of weight loss interventions, where studies in overweight and obese adults without chronic 
conditions have generally shown that 50% of initial weight lost is regained within the first 
year after intervention completion [53].    
Longer-term findings from the Look AHEAD trial, where intervention contact continued over 
multiple years (albeit at a reduced frequency), showed that even with continued contact and 
ongoing resources, weight regain occurred following large initial weight loss [31]. Although, 
after almost 10 years follow-up, intervention participants maintained a mean weight loss of 
6.0% of initial body weight [31]. Improvements in HbA1c observed after the first year of the 
Look AHEAD trial had also attenuated, such that at the final follow-up mean HbA1c levels in 
the intervention group were higher than baseline although still significantly lower than the 
control group [31]. The United Kingdom Prospective Diabetes Study noted that in both its 
intervention groups (conventional versus intensive therapy), although HbA1c reduced 
initially, it steadily increased even with ongoing therapy [47]. These results suggest that 
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lifestyle-based interventions may delay inevitable progressive increases in HbA1c associated 
with advancing disease.   
Limitations  
There are a number of limitations with this review, including the restriction to studies 
published in English language. Studies included were heterogeneous with regard to their 
intervention components, comparison groups evaluated and outcomes reported. Thus random 
effects models were used for meta-analyses and attempts to contact corresponding authors 
were made, with few providing the additional data requested. The methodological quality of 
studies was moderate, and a number of methodological criteria were particularly poorly 
reported: randomization methods, assessor blinding, approaches to missing data and summary 
results presented with effect size and precision estimates. Future studies should pay specific 
attention to these in line with CONSORT guidelines [19].  
Clinical implications  
These results show  that, despite greater understanding of mechanisms underlying obesity 
[54-56], lifestyle-based weight loss interventions over the past decade have continued to 
produce relatively modest results in terms of weight loss and glycemic control. Thus there 
remains an ongoing need to advance our efforts to effectively achieve and maintain weight 
loss and glycemic control in adults with type 2 diabetes. Bariatric surgery is touted as one 
such advancement; however limited health funding does not make this management approach 
viable on a population basis [52,57]. Effective and cost-effective non-surgical treatment 
options will therefore continue to be warranted.  
In type 2 diabetes patients with a BMI ≥27kg/m2, the addition of pharmacotherapy could be 
considered where lifestyle modification alone has been ineffective [58].  Newer diabetes 
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medications, such as glucagon-like peptide 1 (GLP-1) receptor agonists, have the advantage 
of inducing weight loss, in addition to their glucose lowering effects, via their action on 
delaying gastric emptying and increasing satiety, and have been shown to result in weight 
loss of 1-4kg [59,60]. Future lifestyle-based trials in type 2 diabetes patients treated with 
GLP-1 receptor agonists may find greater effectiveness of these interventions in terms of 
initial weight loss and weight loss maintenance, as ongoing suppression of appetite may be 
needed to successfully maintain weight loss [61]. In the most recently published trial included 
in this review [29], only 4% of the sample were treated with a GLP-1 agent at baseline. 
With a growing interest in personalized medicine [62] and the use of patients’ genomic 
information to guide clinical care [62,63], future application of this information to lifestyle 
and behavior change interventions may be possible. Analysis of genetic markers in a 
subsample of participants from the Look AHEAD trial (n=3,899), found that none of the 
previously identified obesity risk single-nucleotide polymorphisms (SNPs), including the fat 
mass and obesity associated gene (FTO), were associated with weight loss at year 1 [64], 
although two novel regions (ABCB11 and TNFRSF11A) were associated with weight loss in 
the lifestyle intervention group only: 1.16kg higher weight per minor allele for ABCB11 
rs484066 and 1.70kg lower weight per allele for TNFRSF11A rs17069904 [65]. In the 
Diabetes Prevention Program, which included adults at risk of type 2 diabetes, the only SNPs 
to show associations with weight loss were at PPARG and MC4R [66,67]. Further, evidence 
from a small number of trials suggests that obesity and diabetes-associated SNPs may 
moderate the effects of macronutrient composition of diets on weight loss [68]. Significant 
associations have also been observed for some obesity-associated SNPs and weight regain 
[66,68]. A move away from a one-size-fits-all approach to a more personalized approach for 
lifestyle and weight management in type 2 diabetes patients, may improve the effectiveness 
of lifestyle-based interventions.  
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Conclusions 
Evidence-based and interdisciplinary approaches, drawing upon clinical/behavioral, 
pharmacological, and genomic evidence need exploration in future trials of lifestyle-based, 
weight loss interventions among those with type 2 diabetes to improve their effectiveness. 
Furthermore, future studies need to report on outcomes that are important for informing 
translation into practice such as cost-effectiveness and longer-term maintenance post-
intervention.    
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Figure 1. PRISMA flow of study selection through the review process 
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Figure 2. Meta-analysis results: Effect of lifestyle-based intervention trials versus usual 
care/brief diabetes education (n=6) on weight change (kg, A), and of lifestyle intervention 
(n=10) on within-group weight change (kg, B) in adults with type 2 diabetes    
A 
B 
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Figure 3. Meta-analysis results: Effect of lifestyle-based intervention trials versus usual care/brief diabetes education on HbA1c (%) in adults 
with type 2 diabetes   
 
 
